Dyne Therapeutics, Inc. (NASDAQ: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has entered into an amendment to its non-dilutive senior secured term loan facility with Hercules Capital, Inc. (NYSE: HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets. The transaction further strengthens the company’s balance sheet as it advances zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) for exon 51 Duchenne muscular dystrophy (DMD) and zeleciment basivarsen (z-basivarsen, also known as DYNE-101) for myotonic dystrophy type 1 (DM1) through critical clinical and regulatory milestones.
“As we continue to focus on diligent execution against our clinical and regulatory objectives, we are pleased to deepen our partnership with Hercules,” said Erick Lucera, chief financial officer.
“This additional access to capital enhances our financial flexibility as we prepare for two potential U.S. launches in the next two years and continue on our mission to deliver functional improvement for individuals living with rare neuromuscular diseases.”
“Hercules is proud to be expanding our support of Dyne as they prepare for the potential approval and commercial launches of z-rostudirsen and z-basivarsen,” said R. Bryan Jadot, Senior Managing Director and Group Head at Hercules Capital.
DYN shares leaped $1.19, or 6.6%, to $19.26.
